The MI-CLAIM-GEN checklist for generative artificial intelligence in health. Read more about The MI-CLAIM-GEN checklist for generative artificial intelligence in health.
Author Correction: Genetically adjusted PSA levels for prostate cancer screening. Read more about Author Correction: Genetically adjusted PSA levels for prostate cancer screening.
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Read more about Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia. Read more about Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia.
Predatory journals: what can we do to protect their prey? Read more about Predatory journals: what can we do to protect their prey?
An organotypic atlas of human vascular cells. Read more about An organotypic atlas of human vascular cells.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Read more about Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Read more about Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Read more about Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Read more about Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
